The price of Ingrezza (valbenazine) is not publicly disclosed as it varies by pharmacy and insurance coverage. However, it is generally considered a high-cost medication.
How much does a prescription for Ingrezza typically cost?
A 30-day supply of Ingrezza can range from approximately $5,000 to over $7,000 without insurance [1]. The exact out-of-pocket cost for patients depends on their insurance plan, including deductibles, copays, and coinsurance.
Are there programs to help with the cost of Ingrezza?
Yes, patients may be eligible for financial assistance programs. Neurocrine Biosciences, the manufacturer of Ingrezza, offers a Savings Program for eligible commercially insured patients to help reduce their out-of-pocket costs. Information on this program is available on the Ingrezza website. For patients with government-funded insurance, other assistance may be available.
How does Ingrezza's price compare to other tardive dyskinesia treatments?
Ingrezza is one of several medications approved for tardive dyskinesia. Other treatments, such as Austedo (deutetrabenazine), also represent significant costs for patients and healthcare systems. Comparing the exact pricing across all available treatments can be complex due to varying dosing and insurance formularies.
When did Ingrezza receive FDA approval?
Ingrezza was approved by the U.S. Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia [2].
What is tardive dyskinesia and how does Ingrezza work?
Tardive dyskinesia is a movement disorder that causes involuntary, repetitive movements, often of the face, tongue, or limbs. Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. By inhibiting VMAT2, it is believed to reduce the amount of dopamine released in the brain, which helps to control the involuntary movements associated with tardive dyskinesia [2].
Are there any notable side effects of Ingrezza that patients should be aware of?
Common side effects of Ingrezza can include somnolence (drowsiness) and insomnia. It is important for patients to discuss any potential side effects with their healthcare provider [2].
What is the patent status of Ingrezza?
Information regarding the specific patents for Ingrezza and their expiry dates is available through resources that track pharmaceutical patents. DrugPatentWatch.com provides data on drug patents, which can be consulted for detailed patent timelines [3].
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [2].
---
Sources
1. https://www.goodrx.com/ingrezza
2. https://www.ingrezza.com/
3. https://drugpatentwatch.com/